Private equity biotech investment landscape in Q3 2025
The biotech investment ecosystem in late August 2025 presents a complex landscape of cautious recovery, selective capital deployment, and strategic
The psychedelics sector faces a brutal financial reckoning as cash burn rates collide with regulatory setbacks
The psychedelics industry entered August 2025 with approximately $1.2 billion in combined cash reserves across six major public companies,
The AI Infrastructure Shift: When Cloud Evangelists Build Their Own Computers
The great wheel of computing infrastructure turns full circle: from centralized mainframes to distributed systems to cloud centralization and now
The weekly term sheet (34)
Biopharma dealmaking slows amid regulatory storm
The week of August 18-23, 2025 marked an unusually subdued period for biopharma transactions,
Company of the week: Palantir
The pharmaceutical industry's adoption of Palantir Technologies reveals a fundamental tension in enterprise software architecture that goes beyond
Fund of the week: ARCH Venture Partners
ARCH Venture Partners has raised over $3 billion for its thirteenth fund, cementing its position as one of biotech'
Collateralized Fund Obligations: The $7 Trillion Question for Biotech Financing
The recent closure of AlpInvest's $1 billion collateralized fund obligation marks a potential inflection point for biotech financing.
The Definitive Guide to Biotech Conference Darwinism: Survival of the Networkiest
Where natural selection meets unnatural hotel ballroom lighting
In the grand ecosystem of biotechnology conferences, where PowerPoint presentations battle for
The silicon valley time machine: why AI's cloud economics are pushing biotech back to the mainframe era
EU AI Act: Pharmaceutical AI Compliance Framework
EU AI Act Classification
High-Risk AI Systems
Pharmaceutical AI Applications
Documentation
Requirements
Risk
Private equity moves deeper into biotech royalties as funding crisis intensifies
Private equity firms deployed $5.42 billion into biotech and pharmaceutical royalty transactions through 2025, marking a 7% increase from
